搜尋
Kazia Therapeutics Ltd
KZIA添加自選
12.620USD
-0.200-1.56%
收盤 07-31 16:00（美東）報價延遲15分鐘
135.44M總市值
虧損本益比TTM
關於 Kazia Therapeutics Ltd 公司
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd簡介
公司代碼KZIA
公司名稱Kazia Therapeutics Ltd
上市日期Sep 01, 1994
CEOFriend (John E)
員工數量- -
證券類型Depository Receipt
年結日Sep 01
公司地址Three International Towers Level 24,
城市SYDNEY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Australia
郵編2000
電話1161298780088
網址https://www.kaziatherapeutics.com/
公司代碼KZIA
上市日期Sep 01, 1994
CEOFriend (John E)
Kazia Therapeutics Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
常見問題
Kazia Therapeutics Ltd的前五大股東是誰？
Kazia Therapeutics Ltd的前五大股東如下：Mr. Steven Roy Stent (Steve) Coffey
有多少機構持有Kazia Therapeutics Ltd(KZIA)的股份？
截至2026Q1，共有50家機構持有Kazia Therapeutics Ltd的股份，合計持有的股份價值約為3.97M，占公司總股份的36.96% 。與2025Q4相比，機構持股有所增加，增幅為3572773.00。